Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

NCT07546500 is registered in ClinicalTrials.gov with K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc as lead sponsor.

NCT NCT07546500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07546500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Lead sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase
Phase 3
Overall status
Recruiting
Start date
April 17, 2026
Completion date
April 30, 2030
Enrollment
420 (estimated)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer